Phase 2 study of MK‐2206, an allosteric inhibitor of AKT, as second‐line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|13|2193-2197

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.13, 2015-07, pp. : 2193-2197

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 4, 2015-11 ,pp. : 463-470

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK Study

By  

Oncology, Vol. 83, Iss. 3, 2012-08 ,pp. : 151-157

Karger

Access to resources Recommend Favorite

Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer

By  

Oncology, Vol. 76, Iss. 4, 2009-03 ,pp. : 270-274

Karger

Access to resources Recommend Favorite

Second-Line Therapy in Refractory Pancreatic Cancer. Results of a Phase II Study

By  

Oncology Research and Treatment, Vol. 32, Iss. 3, 2009-02 ,pp. : 99-102

Karger

Access to resources Recommend Favorite

Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09)

By  

Oncology, Vol. 89, Iss. 2, 2015-03 ,pp. : 70-78

Karger

Access to resources Recommend Favorite